The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain, another positive development in the search for alternatives to opioids. The phase ...

Weak correlations were found between the S-LANSS score and MSK-HQ score, the numerical rating scale (0–10) values for ‘average pain’ and for ‘worst pain’, but not with the MSK-HQ %health ...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which ...

One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get ...

Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in ...

June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people ...

Intensity is the component most often measured in clinical practice and pain management research,6 and multiple tools exist for its quantification: the visual analogue scale (VAS), verbal ...

Inadequate chronic pain care under long-term opioid therapy highlights the need for better Chronic Care Model integration in outpatient settings.

Close to 370,000 British pensioners are facing challenging times due to eligibility rules imposed by the Department for Work ...